Healthcare · Industry
Biotechnology - List & Prices (656 stocks)
All 656 Biotechnology stocks listed, ranked by market capitalization — 14 page(s), 50 per page.
What Are the Leading Biotechnology Stocks?
Prices: Sep 4, 2026 closeThere are 656 publicly traded Biotechnology stocks. The largest by market capitalization are VRTX, REGN, ARGX, MRNA, RVMD, ONC, RPRX, ALNY, INSM, BNTX.
| Company | Ticker | Price | Mkt cap | P/E | Div yield |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | $546.12 | $138.42B | 32.5 | — |
| Regeneron Pharmaceuticals, Inc. | REGN | $827.72 | $85.22B | 20.5 | 0.45% |
| argenx SE | ARGX | $1,033.15 | $64.25B | 40.2 | — |
| Moderna, Inc. | MRNA | $145.55 | $58.11B | — | |
| Revolution Medicines, Inc. | RVMD | $210.02 | $45.01B | — | |
| BeOne Medicines AG | ONC | $358.26 | $40.53B | 64.1 | — |
| Royalty Pharma plc | RPRX | $63.96 | $36.96B | 34.4 | 1.47% |
| Alnylam Pharmaceuticals, Inc. | ALNY | $266.11 | $35.61B | 46.4 | — |
| Insmed Incorporated | INSM | $126.29 | $27.58B | — | |
| BioNTech SE | BNTX | $103.76 | $26.06B | — | |
| Incyte Corporation | INCY | $126.75 | $25.69B | 16.3 | — |
| Roivant Sciences Ltd. | ROIV | $34.93 | $25.23B | — | |
| Genmab A/S | GMAB | $33.60 | $20.65B | 27.1 | — |
| Ascendis Pharma A/S | ASND | $270.56 | $17.75B | 20.9 | — |
| Jazz Pharmaceuticals plc | JAZZ | $246.81 | $16.02B | 16.9 | — |
| BridgeBio Pharma, Inc. | BBIO | $74.84 | $14.63B | — | |
| Exelixis, Inc. | EXEL | $59.01 | $14.62B | 18.6 | — |
| Summit Therapeutics Inc. | SMMT | $17.61 | $14.04B | — | |
| BioMarin Pharmaceutical Inc. | BMRN | $66.53 | $12.88B | 179.8 | — |
| Halozyme Therapeutics, Inc. | HALO | $110.19 | $12.51B | 32.3 | — |
| Madrigal Pharmaceuticals, Inc. | MDGL | $541.08 | $12.50B | — | |
| Arrowhead Pharmaceuticals, Inc. | ARWR | $86.34 | $12.20B | — | |
| Corcept Therapeutics Incorporated | CORT | $111.62 | $12.07B | 248.0 | — |
| Bio-Techne Corporation | TECH | $72.43 | $11.36B | 62.4 | 0.44% |
| Axsome Therapeutics, Inc. | AXSM | $206.68 | $10.83B | — | |
| Krystal Biotech, Inc. Common Stock | KRYS | $358.24 | $10.60B | 44.8 | — |
| Apogee Therapeutics, Inc. | APGE | $135.07 Sep 3, 2026 | $10.22B | — | |
| Cytokinetics, Incorporated | CYTK | $72.72 | $10.11B | — | |
| ABIVAX Société Anonyme | ABVX | $114.79 | $10.02B | — | |
| Praxis Precision Medicines, Inc. | PRAX | $351.81 | $9.82B | — | |
| Nuvalent Inc | NUVL | $123.96 Jul 21, 2026 | $9.81B | — | |
| Kymera Therapeutics, Inc. | KYMR | $117.39 | $9.66B | — | |
| Ionis Pharmaceuticals, Inc. | IONS | $58.09 | $9.65B | — | |
| Protagonist Therapeutics, Inc. | PTGX | $145.72 | $9.43B | 141.5 | — |
| Vaxcyte, Inc. | PCVX | $61.16 | $9.10B | — | |
| Crinetics Pharmaceuticals, Inc. | CRNX | $84.95 Sep 2, 2026 | $9.01B | — | |
| TG Therapeutics, Inc. | TGTX | $55.99 | $8.57B | 20.4 | — |
| ImmunityBio, Inc. | IBRX | $8.08 | $8.56B | — | |
| Immunovant, Inc. | IMVT | $39.25 | $8.11B | — | |
| Spyre Therapeutics, Inc. | SYRE | $88.98 | $7.85B | — | |
| Twist Bioscience Corporation | TWST | $124.72 | $7.82B | — | |
| Belite Bio, Inc | BLTE | $193.61 | $7.80B | — | |
| Caris Life Sciences, Inc. | CAI | $25.07 | $7.09B | 2.6 | — |
| Rhythm Pharmaceuticals, Inc. Common Stock | RYTM | $102.74 | $7.07B | — | |
| Cidara Therapeutics, Inc. | CDTX | $221.38 Jan 8, 2026 | $6.96B | — | |
| Merus N.V. | MRUS | $90.00 Jan 2, 2026 | $6.83B | — | |
| Scholar Rock Holding Corporation | SRRK | $55.33 | $6.74B | — | |
| Arcellx Inc | ACLX | $115.07 May 15, 2026 | $6.73B | — | |
| CG Oncology, Inc. | CGON | $74.67 | $6.62B | — | |
| Centessa Pharmaceuticals plc | CNTA | $40.50 Jun 29, 2026 | $6.16B | — |
Vertex Pharmaceuticals Incorporated
Healthcare / Biotechnology
- Market Cap
- $138.42B
- P/E
- 32.5
Regeneron Pharmaceuticals, Inc.
Healthcare / Biotechnology
- Market Cap
- $85.22B
- P/E
- 20.5
- Dividend Yield
- 0.45%
argenx SE
Healthcare / Biotechnology
- Market Cap
- $64.25B
- P/E
- 40.2
Moderna, Inc.
Healthcare / Biotechnology
- Market Cap
- $58.11B
- P/E
- unprofitable
Revolution Medicines, Inc.
Healthcare / Biotechnology
- Market Cap
- $45.01B
- P/E
- unprofitable
BeOne Medicines AG
Healthcare / Biotechnology
- Market Cap
- $40.53B
- P/E
- 64.1
Royalty Pharma plc
Healthcare / Biotechnology
- Market Cap
- $36.96B
- P/E
- 34.4
- Dividend Yield
- 1.47%
Alnylam Pharmaceuticals, Inc.
Healthcare / Biotechnology
- Market Cap
- $35.61B
- P/E
- 46.4
Insmed Incorporated
Healthcare / Biotechnology
- Market Cap
- $27.58B
- P/E
- unprofitable
BioNTech SE
Healthcare / Biotechnology
- Market Cap
- $26.06B
- P/E
- unprofitable
Incyte Corporation
Healthcare / Biotechnology
- Market Cap
- $25.69B
- P/E
- 16.3
Roivant Sciences Ltd.
Healthcare / Biotechnology
- Market Cap
- $25.23B
- P/E
- unprofitable
Genmab A/S
Healthcare / Biotechnology
- Market Cap
- $20.65B
- P/E
- 27.1
Ascendis Pharma A/S
Healthcare / Biotechnology
- Market Cap
- $17.75B
- P/E
- 20.9
Jazz Pharmaceuticals plc
Healthcare / Biotechnology
- Market Cap
- $16.02B
- P/E
- 16.9
BridgeBio Pharma, Inc.
Healthcare / Biotechnology
- Market Cap
- $14.63B
- P/E
- unprofitable
Exelixis, Inc.
Healthcare / Biotechnology
- Market Cap
- $14.62B
- P/E
- 18.6
Summit Therapeutics Inc.
Healthcare / Biotechnology
- Market Cap
- $14.04B
- P/E
- unprofitable
BioMarin Pharmaceutical Inc.
Healthcare / Biotechnology
- Market Cap
- $12.88B
- P/E
- 179.8
Halozyme Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $12.51B
- P/E
- 32.3
Madrigal Pharmaceuticals, Inc.
Healthcare / Biotechnology
- Market Cap
- $12.50B
- P/E
- unprofitable
Arrowhead Pharmaceuticals, Inc.
Healthcare / Biotechnology
- Market Cap
- $12.20B
- P/E
- unprofitable
Corcept Therapeutics Incorporated
Healthcare / Biotechnology
- Market Cap
- $12.07B
- P/E
- 248.0
Bio-Techne Corporation
Healthcare / Biotechnology
- Market Cap
- $11.36B
- P/E
- 62.4
- Dividend Yield
- 0.44%
Axsome Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $10.83B
- P/E
- unprofitable
Krystal Biotech, Inc. Common Stock
Healthcare / Biotechnology
- Market Cap
- $10.60B
- P/E
- 44.8
Apogee Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $10.22B
- P/E
- unprofitable
Cytokinetics, Incorporated
Healthcare / Biotechnology
- Market Cap
- $10.11B
- P/E
- unprofitable
ABIVAX Société Anonyme
Healthcare / Biotechnology
- Market Cap
- $10.02B
- P/E
- unprofitable
Praxis Precision Medicines, Inc.
Healthcare / Biotechnology
- Market Cap
- $9.82B
- P/E
- unprofitable
Nuvalent Inc
Healthcare / Biotechnology
- Market Cap
- $9.81B
- P/E
- unprofitable
Kymera Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $9.66B
- P/E
- unprofitable
Ionis Pharmaceuticals, Inc.
Healthcare / Biotechnology
- Market Cap
- $9.65B
- P/E
- unprofitable
Protagonist Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $9.43B
- P/E
- 141.5
Vaxcyte, Inc.
Healthcare / Biotechnology
- Market Cap
- $9.10B
- P/E
- unprofitable
Crinetics Pharmaceuticals, Inc.
Healthcare / Biotechnology
- Market Cap
- $9.01B
- P/E
- unprofitable
TG Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $8.57B
- P/E
- 20.4
ImmunityBio, Inc.
Healthcare / Biotechnology
- Market Cap
- $8.56B
- P/E
- unprofitable
Immunovant, Inc.
Healthcare / Biotechnology
- Market Cap
- $8.11B
- P/E
- unprofitable
Spyre Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $7.85B
- P/E
- unprofitable
Twist Bioscience Corporation
Healthcare / Biotechnology
- Market Cap
- $7.82B
- P/E
- unprofitable
Belite Bio, Inc
Healthcare / Biotechnology
- Market Cap
- $7.80B
- P/E
- unprofitable
Caris Life Sciences, Inc.
Healthcare / Biotechnology
- Market Cap
- $7.09B
- P/E
- 2.6
Rhythm Pharmaceuticals, Inc. Common Stock
Healthcare / Biotechnology
- Market Cap
- $7.07B
- P/E
- unprofitable
Cidara Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $6.96B
- P/E
- unprofitable
Merus N.V.
Healthcare / Biotechnology
- Market Cap
- $6.83B
- P/E
- unprofitable
Scholar Rock Holding Corporation
Healthcare / Biotechnology
- Market Cap
- $6.74B
- P/E
- unprofitable
Arcellx Inc
Healthcare / Biotechnology
- Market Cap
- $6.73B
- P/E
- unprofitable
CG Oncology, Inc.
Healthcare / Biotechnology
- Market Cap
- $6.62B
- P/E
- unprofitable
Centessa Pharmaceuticals plc
Healthcare / Biotechnology
- Market Cap
- $6.16B
- P/E
- unprofitable
Showing 1–50 of 656 · ranked by market capitalization
Where the trailing year was a loss, P/E appears as “unprofitable”; a dash is missing data. Ranked by market capitalization. Prices are the most recent daily close.
Which Biotechnology Stocks Are Reasonably Valued?
Prices: Sep 4, 2026 closeAmong the 50 largest Biotechnology companies, Caris Life Sciences, Inc. (CAI) trades at the lowest trailing P/E ratio, 2.6. The industry average is 27.7.
| Company | Ticker | Price | Mkt cap | P/E | Div yield |
|---|---|---|---|---|---|
| Caris Life Sciences, Inc. | CAI | $25.07 | $7.09B | 2.6 | — |
| Incyte Corporation | INCY | $126.75 | $25.69B | 16.3 | — |
| Jazz Pharmaceuticals plc | JAZZ | $246.81 | $16.02B | 16.9 | — |
| Exelixis, Inc. | EXEL | $59.01 | $14.62B | 18.6 | — |
| TG Therapeutics, Inc. | TGTX | $55.99 | $8.57B | 20.4 | — |
Ranked by trailing twelve-month P/E, lowest first. Companies that report no P/E are not listed. Rankings cover the 50 largest Biotechnology companies by market capitalization.
Key facts
As of September 4, 2026, 656 Biotechnology stocks are listed on NYSE/NASDAQ and TSX.
The largest by market capitalization is Vertex Pharmaceuticals Incorporated (VRTX) at $138.42B.
The median P/E across the Biotechnology industry is 12.6.
Biotechnology Industry Overview
From the data · Sep 4, 2026The Biotechnology industry, part of the Healthcare sector, includes 656 publicly traded companies with a combined market capitalization of $1.46T. The industry is led by Vertex Pharmaceuticals Incorporated (VRTX), Regeneron Pharmaceuticals, Inc. (REGN), argenx SE (ARGX).
Among the 656 listed Biotechnology companies, market capitalizations range from $138.42B (Vertex Pharmaceuticals Incorporated) down to $45.01B (Revolution Medicines, Inc.), highlighting the wide size disparity across the industry. The average market cap across the industry is $2.23B, reflecting a mix of established large-cap players and smaller growth-oriented companies.
Biotechnology Industry Valuation
The Biotechnology industry currently trades at an average price-to-earnings (P/E) ratio of 27.7. This elevated multiple indicates that investors are pricing in strong future earnings growth across Biotechnology companies. Note that some companies in the industry report no P/E ratio, typically because they are currently unprofitable or in early growth stages.
Biotechnology Dividend Profile
7 out of 656 Biotechnology companies (1%) currently pay dividends to shareholders. The average dividend yield across dividend-paying Biotechnology stocks is 3.56%. Most Biotechnology companies reinvest earnings into growth rather than paying dividends, which is typical for earlier-stage or high-growth industries.
Frequently Asked Questions
What are the leading Biotechnology stocks?
The largest Biotechnology stocks by market capitalization are Vertex Pharmaceuticals Incorporated (VRTX), Regeneron Pharmaceuticals, Inc. (REGN), argenx SE (ARGX), Moderna, Inc. (MRNA), Revolution Medicines, Inc. (RVMD). All 656 companies are ranked by market cap on this page.
Where can I find a complete list of Biotechnology stocks?
This page is the complete list: 656 Biotechnology companies across 14 page(s), 50 per page, ranked by market capitalization — including VRTX, REGN, ARGX, MRNA, RVMD.
How many Biotechnology stocks are there?
There are 656 publicly traded Biotechnology companies listed on major US exchanges, ranging from Vertex Pharmaceuticals Incorporated (VRTX) to Revolution Medicines, Inc. (RVMD) by market capitalization. This directory spans 14 pages, with all companies sorted by market cap for easy comparison.
Which Biotechnology stocks are reasonably valued?
Among the 50 largest Biotechnology companies, Caris Life Sciences, Inc. (CAI) carries the lowest trailing P/E at 2.6, against an industry average of 27.7.
Which Biotechnology stocks have the highest dividend yield?
7 of the 656 Biotechnology companies (1%) pay a dividend, with an average yield of 3.56% among payers. The highest yield among the 50 largest is Royalty Pharma plc (RPRX) at 1.47%.
Explore Biotechnology Stocks on StockVS
StockVS provides detailed fundamental data, historical price charts, and side-by-side comparisons for all 656 Biotechnology companies. Browse individual stock pages for in-depth analysis, or use our comparison tool to evaluate two Biotechnology stocks head to head. All data is updated regularly to reflect the latest available financials.